Chemotherapy Treatment Articles & Analysis
55 news found
This trial originally demonstrated that the combination of tremelimumab, durvalumab, and chemotherapy significantly increases progression-free survival (PFS) and overall survival (OS) versus chemotherapy in patients with metastatic NSCLC, which lead to approval of this regiment globally in 1L mNSCLC. The SOPHiA GENETICS study used cutting-edge multimodal machine ...
Additionally, the darolutamide combination showed consistent benefits across clinically relevant secondary endpoints, with the overall incidence of treatment-emergent adverse events being similar between treatment arms. ...
ByBayer AG
” “Despite recent advances, there still remains a need for treatments that extend survival and delay disease progression while maintaining quality of life. ...
ByBayer AG
Additional indication is for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations Represents the fifth indication for PEMFEXY, a ready-to-use liquid with a unique J-code approved to treat non-squamous non-small cell lung cancer and mesothelioma Eagle Pharmaceuticals, Inc. ...
The end goals are to determine whether this targeted method of delivering chemotherapy can extend survival while also improving quality of life. Although pancreatic cancer treatment has improved, pancreatic cancer patients continue to have poor outcomes – partially due to the tissue surrounding the tumor hampering intravenously delivered ...
ByxCures
(“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended release (ONA-XR), the company’s novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, ...
Badhey, MD, Department of Otolaryngology, University of Massachusetts Chan Medical School, and lead author, stated, “We understand that SCC patients with positive margins after initial surgery are known to have increased risk of local recurrence, poorer rates of progression-free survival, and a need for adjuvant treatments such as radiotherapy, chemotherapy ...
BNCT has the potential to deliver highly effective, cell-localized radiation therapy to treat tumors with minimal impact on the patient's quality of life compared to other available treatment options, such as radiation, chemotherapy or biological treatment modalities. ...
Miller and Marshall Pitz, describe the activity of LNP-siSAT1 against the GB cells and its ability to further sensitized them towards radiation and chemotherapy providing an avenue to increase treatment efficacy and hence potentially increase survival. ...
The publication, titled “Enhanced Progression-Free Survival in a Phase 2 Trial of Personal Dendritic Cell Vaccines in Patients with Newly Diagnosed Glioblastoma” can be viewed online at: http://www.doi.org/10.29011/2574-710X.010149 “The strengths of our approach include its lack of toxicity and the ability to pair it with other treatment modalities such as ...
Overall incidence of adverse events (AEs) was similar between treatment arms, despite longer treatment exposure for those treated with darolutamide (median 41.0 versus 16.7 months). ...
ByBayer AG
The study involves patients with recently diagnosed metastatic pancreatic adenocarcinoma who are scheduled to receive chemotherapy treatment with gemcitabine and abraxane. Vault Health’s decentralized research capabilities will allow Faeth to extend the NEAAR clinical trial beyond physical clinical trial sites to patients living across the country. ...
ByxCures
“This approval adds a different treatment approach for mHSPC patients and their physicians to choose ...
ByBayer AG
“We believe that our novel off-the-shelf personalized immunotherapy may offer a safe and effective targeted personalized treatment option for advanced prostate cancer patients who failed the current standard of care,” Dr. ...
(Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for VBI-1901, a bivalent gB/pp65 immunotherapeutic vaccine candidate for the treatment of glioblastoma (GBM). In June 2021, the FDA ...
“We continue to be motivated by the data seen in this Phase 2a study of VBI-1901 as we endeavor to provide new treatment options to patients with very few available to them,” said David E. ...
” The Cellworks Biosimulation Platform simulates how a patient's personalized genomic disease model will respond to therapies prior to treatment and identifies novel drug combinations for treatment-refractory patients. ...
BNCT has the potential to deliver highly effective and cell-localized radiation therapy to treat tumors with minimal impact on the patient’s quality of life compared to other radiation, chemotherapy or biological treatment modalities currently in use. Neutron Therapeutics Inc. and the Helsinki University Hospital are collaborating to launch the first ...
Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for the oral androgen receptor inhibitor (ARi) darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The application is being conducted under the FDA Oncology Center of Excellence’s (OCE) ...
ByBayer AG
In the past decade, pharmaceutical companies have been reluctant to re-address pain treatments following the opioids crisis. However, we see a change on the horizon. ...